" class="no-js "lang="en-US"> Compugen Announces Collaboration Expansion with Bristol Myers Squibb Alongside $20 Million Equity Investment - Medtech Alert
Saturday, December 02, 2023

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Compugen Announces Collaboration Expansion with Bristol Myers Squibb Alongside $20 Million Equity Investment | Pharmtech Focus

November 11 2021

Compugen Announces Collaboration Expansion with Bristol Myers Squibb Alongside $20 Million Equity Investment

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that Bristol Myers Squibb (NYSE: BMY) completed its $20 million investment in Compugen  in consideration for the issuance of 2,332,815 shares of Compugen purchased at $8.57333 per share, representing a 33% premium over the closing price on November 9, 2021.

As part of the expansion of the collaboration, a joint steering committee has been formed to facilitate strategic oversight and guidance for the programs run under the collaboration. This will run alongside the existing joint development committee which acts at an operational level.

“Bristol Myers Squibb’s strategic investment in Compugen strengthens our relationship and the goal of both companies to take forward our clinical studies conducted under our collaboration in bringing innovative therapies to cancer patients,” said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. “We value Bristol Myers Squibb’s continued support of Compugen and in our evaluation of our DNAM axis hypothesis by testing COM701 in combination with nivolumab as a dual combination and in combination with nivolumab and BMS-986207 as a triple combination targeting PVRIG, PD-1 and TIGIT.”

People In This Post

Anat Cohen-Dayag

Anat Cohen-Dayag

Companies In This Post

Bristol Myers Squibb | Pharmtech Focus

Bristol Myers Squibb
Compugen | Pharmtech Focus

Compugen
  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

    Clinical Trials

     Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS

    Clinical Trials

     Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board

    Appointments

     Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera

    News

     Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic

    Clinical Trials

     Read more
More On